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Introduction {#sec001}
============

Tuberculosis (TB) is a serious health problem, and China is one of the countries with high burden of TB \[[@pone.0166052.ref001],[@pone.0166052.ref002]\]. One of causes for the difficulty in controlling tuberculosis is TB drug resistance \[[@pone.0166052.ref003]--[@pone.0166052.ref006]\]. In recent years, there has been a rising trend in the number of multi-drug resistant *Mycobacterium tuberculosis* (MTB) clinical isolates \[[@pone.0166052.ref005]--[@pone.0166052.ref009]\].

Currently, to guide the clinically rational use of drugs, routine *in vitro* drug susceptibility tests for TB are commonly conducted in many laboratories \[[@pone.0166052.ref010]--[@pone.0166052.ref013]\]. However, despite therapy based on the test results, there are still some cases of treatment failure \[[@pone.0166052.ref014]\]. We speculate that one of the causes for this may be related to changes in MTB resistance under hypoxia.

The routine TB drug susceptibility tests in vitro are performed under aerobic conditions (21% of oxygen from the atmosphere). However, in vivo conditions such as granuloma, caseous necrosis tissue, or macrophages are hypoxic in nature \[[@pone.0166052.ref015]--[@pone.0166052.ref017]\]. If MTB resides in these tissues, the features of its biological metabolism might change \[[@pone.0166052.ref015]--[@pone.0166052.ref018]\], which may lead to variation in its resistance and growth characteristics. To identify whether the drug sensitivity and growth characteristics of MTB under hypoxic conditions are different from those under aerobic conditions, and to explore the related mechanisms, we conducted the following related research, using a large sample of MTB clinical isolates.

Methods and Materials {#sec002}
=====================

Ethics statement {#sec003}
----------------

This study was approved by the Shanghai Pulmonary Hospital Affiliated to Tongji University School of Medicine Ethics Committee. Subjects were treated in accordance with the Helsinki Declaration on the participation of human subjects in medical research. Written informed consent was obtained from each participant.

Collection of strains and drug susceptibility testing {#sec004}
-----------------------------------------------------

Two hundred and forty-five MTB clinical isolates were obtained from the Department of Clinical Laboratory Medicine at Shanghai Pulmonary Hospital between 2013 and 2015 ([S1 Fig](#pone.0166052.s001){ref-type="supplementary-material"}). Routine drug susceptibility tests were performed using a commercial microplate kit (Yibaishi Biotech, Inc., Shen-zhen, China) on the BACTECT 960 System (Becton Dickinson, Franklin Lakes, NJ) under conventional aerobic conditions, and hypoxic drug susceptibility testing was conducted under hypoxic conditions by covering 50 μl of paraffin oil. In this study, susceptibility to first-line drugs like isoniazid (INH), ethambutol (EMB), rifampicin (RMP), and streptomycin (SM) was analyzed. The minimum inhibitory concentrations (MICs) were recorded. The standard laboratory strain H37Rv was purchased from the Chinese National Institute for Food and Drug Control.

Establishment of the hypoxia model and analysis of growth characteristics of MTB {#sec005}
--------------------------------------------------------------------------------

Aerobic cultures (NRP-2) by Wayne\'s method were used to establish the hypoxia model described in this report \[[@pone.0166052.ref015],[@pone.0166052.ref019]\]. Population growth curves were determined by a Bioscreen Growth Curve Instrument (Bioscreen C, Helsinki, Finland), using a honeycomb plate with 100 wells (Bioscreen C, Helsinki, Finland). Briefly, 300 μl of 7H9 medium was added to each well, and cultured with shaking at 37°C. The optical density was measured as absorbance at 600 nm after every 2 hours. Hypoxia conditions were established by covering 50 μl of paraffin oil. If both growth curves under the aerobic and hypoxic conditions were completely in accord with the Webster\'s model, the model of hypoxia was considered successful. The growth characteristics analysis was performed under aerobic as well as hypoxic conditions.

Enumerating MTB clinical strains in macrophages {#sec006}
-----------------------------------------------

Clinical isolates of MTB were cultured under both aerobic and hypoxic conditions. MTB isolates grown to the logarithmic phase were used to infect THP1 macrophages. At different time points after infection, the infected cells were washed twice with PBS and lysed for 10 minutes using Triton X-100. Subsequently, the lysed mixture was inoculated onto 7H9 solid plates and cultured at 37°C for 4 weeks. Finally, MTB clones were counted.

Effect of hypoxia on gene expression in MTB clinical isolates {#sec007}
-------------------------------------------------------------

After reviewing previous studies \[[@pone.0166052.ref011],[@pone.0166052.ref015]--[@pone.0166052.ref043]\], the relevant regulatory genes for efflux pumps and transcription factors likely to affect drug resistance in MTB ([Table 1](#pone.0166052.t001){ref-type="table"}) were selected and their expression was quantified by RT-PCR. Briefly, 25 ml of culture was used to extract RNA upon cell lysis via the TRIzol bead beater method and phenol extraction \[[@pone.0166052.ref035]\]. RNA concentrations were determined using a Nanodrop 2000 (NanoDrop Technologies). RNA was treated with DNase as previously described \[[@pone.0166052.ref035]\] and reverse-transcribed using the High Capacity RNA-to-cDNA kit (Applied Biosystems) following the manufacturers' instructions. RT PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems), as previously described \[[@pone.0166052.ref035]\]. PCR primers for the above genes are specified in [S1 Table](#pone.0166052.s008){ref-type="supplementary-material"}. The tests in this study were performed on the 7500 Fast Dx Real-Time PCR System (Applied Biosystems). The reaction conditions were as follows: 95°C for 60 s, 40 cycles of 95°C for 5 s, 62°C for 8 s, and 72°C for 20 s, followed by a melt curve analysis.
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###### The characteristics of the testing genes in this study.

![](pone.0166052.t001){#pone.0166052.t001g}

  Category                      Gene name   Rv number   Description
  ----------------------------- ----------- ----------- ---------------------------------------------------------------------------
  INH regulation gene           FbpC        Rv0129c     Diacylglycerol acyltransferase/mycolyltransferase Ag85C
  INH regulation gene           EfpA        Rv2846c     MFS-type transporter EfpA
  INH regulation gene           FadE23      Rv3140      Acyl-CoA dehydrogenase FadE23 
  RIF regulation gene           RegX3       Rv0491      Two component sensory transduction protein RegX
  RIF regulation gene           SigF        Rv3286c     RNA polymerase sigma factor SigF
  RIF regulation gene           MprA        Rv0981      Two-component response regulator MrpA
  Efflux pump regulation gene   Rv0194      Rv0194      Multidrug ABC transporter ATPase/permease
  Efflux pump regulation gene   WhiB7       Rv3197A     Transcriptional regulator WhiB7
  Efflux pump regulation gene   Rv2136c     Rv2136c     Undecaprenyl-diphosphatase
  Efflux pump regulation gene   Rv1410c     Rv1410c     Aminoglycosides/tetracycline-transport integral membrane protein
  Transcript regulation gene    Rv0081      Rv0081      HTH-type transcriptional regulator
  Transcript regulation gene    Rv0324      Rv0324      Transcriptional regulator
  Transcript regulation gene    LipY        Rv3097c     Triacylglycerol lipase Lip
  Transcript regulation gene    LipX        Rv1169c     Lipase LipX
  Transcript regulation gene    Pks3        Rv1180      Polyketide beta-ketoacyl synthase
  Transcript regulation gene    MutA        Rv1492      Methylmalonyl-CoA mutase small subunit
  Transcript regulation gene    AccA3       Rv3285      Bifunctional protein acetyl-/propionyl-CoA carboxylase subunit alpha AccA
  Transcript regulation gene    WhiB3       Rv3416      Redox-responsive transcriptional regulator WhiB3
  Transcript regulation gene    KstR        Rv3574      HTH-type transcriptional regulator KstR
  Transcript regulation gene    Lsr2        Rv3597c     Iron-regulated H-NS-like protein
  Transcript regulation gene    DevR        Rv3133c     Two component transcriptional regulator dosR
  Transcript regulation gene    IciA        Rv1985c     HTH-type transcriptional regulator 
  Transcript regulation gene    DATIN       Rv0079      Dormancy Associated Translation Inhibitor

Statistical analysis {#sec008}
--------------------

SPSS software (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis of results. Chi-square test, non-parametric test, and one-way analysis of variance (ANOVA) were performed to analyze the different data in this study. A p-value less than 0.05 was considered statistically significant.

Results {#sec009}
=======

Drug resistance of clinical strains under hypoxic conditions {#sec010}
------------------------------------------------------------

In this study, the MICs of 245 MTB clinical isolates determined by the microplate method were found to be identical with those obtained by the BACTECT 960 System ([S2 Table](#pone.0166052.s009){ref-type="supplementary-material"}).

Addition of liquid paraffin to the microplate allowed the formation of a curve similar to that in the Wayne's aerobic model, as determined by OD ([S2 Fig](#pone.0166052.s002){ref-type="supplementary-material"}). Therefore, construction of a hypoxic growth model in the microplate was successful.

Upon analyzing the MICs of 245 clinical isolates, 68.2% (167/245) were determined as MTB strains of unchanged drug sensitivity (MTB-UDS), whereas others (31.8%, 78/245) belonged to MTB strains of changed drug sensitivity (MTB-CDS; [Fig 1](#pone.0166052.g001){ref-type="fig"}).

![Comparison of the rates of changed MTB strains of drug sensitivity and unchanged MTB strains of drug sensitivity in 245 strains clinical isolates under hypoxia.\
MTB-UDS: changed MTB strains of drug sensitivity; MTB-CDS: unchanged MTB strains of drug sensitivity.](pone.0166052.g001){#pone.0166052.g001}

The stratified analysis of the drug susceptibility test result showed that the overall sensitivity in MTB-CDS was significantly lower than that in MTB-UDS (12.8% *vs*. 48.5%, *p* \< 0.05). Resistance to single drugs in MTB-CDS was also significantly higher than that in MTB-CDS (35.9% *vs*. 10.2%, *p* \< 0.05); multi-drug resistance in MTB-CDS was also significantly higher than that in MTB-UDS (23.1% *vs*. 12%, *p* \< 0.05; [Fig 2](#pone.0166052.g002){ref-type="fig"}).

![Comparison of drug resistances of changed MTB strains of drug sensitivity and unchanged MTB strains of drug sensitivity.\
MTB-UDS: changed MTB strains of drug sensitivity under hypoxia; MTB-CDS: unchanged MTB strains of drug sensitivity under hypoxia; S: sensitive; SDR: single drug resistance; MDR: multi-drug resistance; DMR: drug multi-resistance.](pone.0166052.g002){#pone.0166052.g002}

Overall, under hypoxic conditions, the rate of MTB clinical isolates for which the MICs of first line drugs were increased was 38.5% (30/78), whereas that for which the MICs were decreased was 23% (18/78; [S3 Fig](#pone.0166052.s003){ref-type="supplementary-material"}).

Growth characteristics of MTB clinical isolates under hypoxic conditions {#sec011}
------------------------------------------------------------------------

Based on the growth curve analysis, the growth of MTB-CDS was slower that of MTB-UDS under aerobic conditions; whereas under hypoxic conditions, the growth curves of MTB-CDS nearly coincided with those of MTB-UDS, ([Fig 3](#pone.0166052.g003){ref-type="fig"}) indicating that MTB-CDS can suitably grow under hypoxia.

![Growth curves of MTB clinical isolates under aerobic and hypoxic conditions.\
MTB-UDS: changed MTB strains of drug sensitivity; MTB-CDS: unchanged MTB strains of drug sensitivity.](pone.0166052.g003){#pone.0166052.g003}

Analysis of survival ability of MTB clinical strains in macrophages under hypoxic conditions {#sec012}
--------------------------------------------------------------------------------------------

Examination of the MTB survival ability in macrophages at different times under aerobic conditions showed that the difference in survival between the MTB-CDS and MTB-UDS with increasing time was not statistically significant (*p* \> 0.05; [Fig 4](#pone.0166052.g004){ref-type="fig"}); whereas under hypoxic conditions, the survival of the MTB-CDS was significantly higher than that of MTB-UDS (*p* \< 0.05; [Fig 5](#pone.0166052.g005){ref-type="fig"}).

![Survivability of changed MTB strains of drug sensitivity and unchanged MTB strains of drug sensitivity in macrophage cell under aerobic conditions.\
MTB-UDS: changed MTB strains of drug sensitivity; MTB-CDS: unchanged MTB strains of drug sensitivity.](pone.0166052.g004){#pone.0166052.g004}

![Survivability of changed MTB strains of drug sensitivity and unchanged MTB strains of drug sensitivity in macrophage cell under hypoxic conditions.](pone.0166052.g005){#pone.0166052.g005}

Gene expression potentially related to resistance in MTB {#sec013}
--------------------------------------------------------

According to the results of fluorescence quantitative PCR, the expression of some genes, including RegX3 (involving RIF resistance), Rv0194 (efflux pump gene), four genes related to transcription regulation (KstR, DosR, Rv0081 and WhiB3) and gene related to translation regulation (DATIN), was significantly upregulated under hypoxic conditions compared to that under aerobic conditions (*p* \< 0.05; [S4](#pone.0166052.s004){ref-type="supplementary-material"}, [S5](#pone.0166052.s005){ref-type="supplementary-material"}, [S6](#pone.0166052.s006){ref-type="supplementary-material"} and [S7](#pone.0166052.s007){ref-type="supplementary-material"} Figs).

Discussion {#sec014}
==========

Previous studies have shown that MTB can survive under hypoxic conditions \[[@pone.0166052.ref023],[@pone.0166052.ref044],[@pone.0166052.ref045]\]. In this study, MICs of 245 MTB clinical isolates, determined by the microplate method, were found to be identical with those obtained from the BACTECT 960 System under aerobic conditions. The Wayne model is currently recognized as a reliable *in vitro* model for simulating *in vivo* environments such as MTB dormancy or hypoxic environments. In this study, we observed almost coinciding curves upon comparing the growth curve of the MTB culture systems with H37Rv, which was cultured under both aerobic and anaerobic environments. Therefore, the growth model of hypoxia was successfully established. By analyzing the MICs of 245 clinical isolates, we found that about one-third of the MTB strains were MTB-CDS, whereas the others belonged to MTB-UDS.

Further stratified analysis of the results of drug sensitivity testing showed that the overall sensitivity of MTB-CDS was significantly lower than that of MTB-UDS, and the resistance to single drugs and multiple drugs in MTB-CDS were both significantly higher than those in MTB-UDS. Overall, under hypoxic conditions, the proportion of MTB clinical isolates for which the MICs of first line drugs were increased was 38.5%.

Therefore, we can conclude that there was a significant change in drug resistance of some MTB strains under hypoxic conditions. Considering that routine drug susceptibility testing is unable to completely reflect the actual resistance in MTB, we suggest that drug susceptibility tests should also be conducted under hypoxic conditions to exclude hypoxia resistance in MTB, especially for cases showing initial therapeutic failure.

Based on the growth curve analysis, the growth of MTB-CDS was slower than that of MTB-UDS under aerobic conditions, whereas under hypoxic conditions, the growth curves of MTB-CDS were nearly similar to those of MTB-UDS, indicating that MTB-CDS are more suitable for survival under hypoxia.

By determining the survival of MTB in macrophages at different times, we found that the difference in survival under aerobic conditions was not statistically significant between the MTB-UDS and MTB-CDS with increasing time; however, under hypoxic conditions, the survival of MTB-UDS was significantly higher than that of MTB-CDS. This further proves that MTB-CDS can survive under hypoxic conditions.

A previous study has shown that the dormancy survival regulon (DosR regulon) is chiefly responsible for encoding the dormancy related functions of MTB, and appears to be involved in translation regulation through the interaction of its product with bacterial ribosomal subunits \[[@pone.0166052.ref046]\]. One of the DosR regulon proteins, DATIN, encoded by the gene Rv0079, can stimulate macrophages and peripheral blood mononuclear cells to secrete important cytokines, which may be significant in granuloma formation and maintenance \[[@pone.0166052.ref047]\]. Additionally, the expression of DATIN in *M*. *bovis* BCG was found to be upregulated under pH stress and micro-aerobic conditions \[[@pone.0166052.ref047]\]. This indicates that MTB survival under hypoxia is closely associated with gene regulation, and some relevant regulatory genes related to drug resistance, such as efflux pumps and transcription factors, are likely involved in MTB drug resistance under hypoxia. According to the results of fluorescence quantitative PCR, the expression of some genes, including RegX3 (involving RIF resistance), Rv0194 (efflux pump gene), four genes related to transcription regulation (KstR, DosR, Rv0081 and WhiB3) and gene related to translation regulation (DATIN), was significantly upregulated under hypoxic conditions compared to that under aerobic conditions. As for other genes such as IciA, we didn't found difference in gene expression. However, the previous study showed that, IciA has a bearing on the functional role of the important regulator of MTB chromosomal replication in the context of latency \[[@pone.0166052.ref048]\]. According to the report, synergy between the N-terminal and C-terminal domains of HupB is essential for its DNA-binding ability, and to modulate the topological features of DNA, which has implications for processes such as DNA compaction, gene regulation, homologous recombination, and DNA repair \[[@pone.0166052.ref049]\]. Thus, we believe that the mechanisms of hypoxia resistance in MTB clinical isolates are associated with the expression of some genes. Moreover, we speculate that the difference in the expression of some genes could result in better survival of MTB-CDS under hypoxia compared to that of MTB-CDS.

Efflux pumps are thought to have emerged for the expulsion of noxious substances from the bacterial cell, thus allowing its survival; increased expression of efflux pumps is associated with resistance to alien substances, including drugs \[[@pone.0166052.ref050]\]. These pumps are often called multi-drug efflux pumps \[[@pone.0166052.ref050]\]. In addition, the expression of drug resistance in MTB is linked with some transcription regulation genes. However, the exact mechanisms involved in hypoxia drug resistance of MTB remain unknown.

In summary, in our study, some MTB clinical isolates showed very good adaptability under hypoxic conditions, better survival in macrophages, and resistance to some anti-tuberculosis drugs. This resulted in incorrect results from routine MTB drug susceptibility testing; hence, we recommend that drug susceptibility tests should be simultaneously conducted under hypoxic conditions, especially for cases with initial therapeutic failure. The mechanisms underlying the effect of hypoxia on drug sensitivity and growth characteristics of MTB still require further study.
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